How much profit has IRIDEX made this year?
IRIDEX has made -8.76 M USD this year.
IRIDEX Net Income 2024
IRIDEX Net Income
-8.76 M USD
Ticker
IRIX
ISIN
US4626841013
WKN
912341
In 2024, IRIDEX's profit amounted to -8.76 M USD, a -8.5% increase from the -9.57 M USD profit recorded in the previous year.
The IRIDEX Net Income history
| YEAR | NET INCOME (undefined USD) |
|---|---|
| 2026e | -5.94 |
| 2025e | -4.55 |
| 2024e | -8.76 |
| 2023 | -9.57 |
| 2022 | -7.55 |
| 2021 | -5.23 |
| 2020 | -6.33 |
| 2019 | -8.81 |
| 2018 | -12.81 |
| 2017 | -12.87 |
| 2016 | -11.71 |
| 2015 | 0.47 |
| 2014 | 10.04 |
| 2013 | 2.23 |
| 2012 | 1.44 |
| 2011 | 2.61 |
| 2010 | 3.05 |
| 2009 | 2.59 |
| 2008 | -7.37 |
| 2007 | -22.27 |
| 2006 | -5.75 |
| 2005 | 1.67 |
| 2004 | -0.4 |
IRIDEX Revenue, EBIT, Net Income US4626841013 · 912341
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into IRIDEX, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IRIDEX from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IRIDEX’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of IRIDEX. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into IRIDEX’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing IRIDEX’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IRIDEX’s growth potential.
IRIDEX Revenue, EBIT and net profit per share
| Date | IRIDEX Revenue | IRIDEX EBIT | IRIDEX Net Income |
|---|---|---|---|
| 2026e | 70.21 M USD | -5.27 M USD | -5.94 M USD |
| 2025e | 53.35 M USD | -5 M USD | -4.55 M USD |
| 2024e | 50.59 M USD | -7.55 M USD | -8.76 M USD |
| 2023 | 51.87 M USD | -10.01 M USD | -9.57 M USD |
| 2022 | 56.97 M USD | -7.54 M USD | -7.55 M USD |
| 2021 | 53.9 M USD | -7.53 M USD | -5.23 M USD |
| 2020 | 36.35 M USD | -6.58 M USD | -6.33 M USD |
| 2019 | 43.45 M USD | -8.97 M USD | -8.81 M USD |
| 2018 | 42.6 M USD | -12.87 M USD | -12.81 M USD |
| 2017 | 41.59 M USD | -13.03 M USD | -12.87 M USD |
| 2016 | 46.16 M USD | -2.45 M USD | -11.71 M USD |
| 2015 | 41.76 M USD | 290,000 USD | 470,000 USD |
| 2014 | 42.81 M USD | 2.59 M USD | 10.04 M USD |
| 2013 | 38.27 M USD | 2.16 M USD | 2.23 M USD |
| 2012 | 33.86 M USD | -860,000 USD | 1.44 M USD |
| 2011 | 33.16 M USD | 660,000 USD | 2.61 M USD |
| 2010 | 32.31 M USD | 1.19 M USD | 3.05 M USD |
| 2009 | 31.03 M USD | 1.23 M USD | 2.59 M USD |
| 2008 | 48.53 M USD | -2.18 M USD | -7.37 M USD |
| 2007 | 55.53 M USD | -9.43 M USD | -22.27 M USD |
| 2006 | 35.9 M USD | -4.77 M USD | -5.75 M USD |
| 2005 | 37.03 M USD | 1.81 M USD | 1.67 M USD |
| 2004 | 32.81 M USD | -1.08 M USD | -400,000 USD |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 32.81 M USD | -1.08 M USD | -400,000 USD |
| 2005 | 37.03 M USD | 1.81 M USD | 1.67 M USD |
| 2006 | 35.9 M USD | -4.77 M USD | -5.75 M USD |
| 2007 | 55.53 M USD | -9.43 M USD | -22.27 M USD |
| 2008 | 48.53 M USD | -2.18 M USD | -7.37 M USD |
| 2009 | 31.03 M USD | 1.23 M USD | 2.59 M USD |
| 2010 | 32.31 M USD | 1.19 M USD | 3.05 M USD |
| 2011 | 33.16 M USD | 660,000 USD | 2.61 M USD |
| 2012 | 33.86 M USD | -860,000 USD | 1.44 M USD |
| 2013 | 38.27 M USD | 2.16 M USD | 2.23 M USD |
| 2014 | 42.81 M USD | 2.59 M USD | 10.04 M USD |
| 2015 | 41.76 M USD | 290,000 USD | 470,000 USD |
| 2016 | 46.16 M USD | -2.45 M USD | -11.71 M USD |
| 2017 | 41.59 M USD | -13.03 M USD | -12.87 M USD |
| 2018 | 42.6 M USD | -12.87 M USD | -12.81 M USD |
| 2019 | 43.45 M USD | -8.97 M USD | -8.81 M USD |
| 2020 | 36.35 M USD | -6.58 M USD | -6.33 M USD |
| 2021 | 53.9 M USD | -7.53 M USD | -5.23 M USD |
| 2022 | 56.97 M USD | -7.54 M USD | -7.55 M USD |
| 2023 | 51.87 M USD | -10.01 M USD | -9.57 M USD |
| 2024e | 50.59 M USD | -7.55 M USD | -8.76 M USD |
| 2025e | 53.35 M USD | -5 M USD | -4.55 M USD |
| 2026e | 70.21 M USD | -5.27 M USD | -5.94 M USD |
IRIDEX stock margins US4626841013 · 912341
The IRIDEX margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IRIDEX. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IRIDEX.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the IRIDEX's sales revenue. A higher gross margin percentage indicates that the IRIDEX retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the IRIDEX's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the IRIDEX's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IRIDEX's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IRIDEX. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IRIDEX's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
IRIDEX Margin History
| IRIDEX Gross margin | IRIDEX Profit margin | IRIDEX EBIT margin | IRIDEX Profit margin |
|---|---|---|---|
| 2026e | 42.04 % | -7.51 % | -8.46 % |
| 2025e | 42.04 % | -9.37 % | -8.52 % |
| 2024e | 42.04 % | -14.92 % | -17.31 % |
| 2023 | 42.04 % | -19.29 % | -18.45 % |
| 2022 | 44.53 % | -13.24 % | -13.25 % |
| 2021 | 42.36 % | -13.97 % | -9.7 % |
| 2020 | 42.81 % | -18.1 % | -17.41 % |
| 2019 | 41.29 % | -20.64 % | -20.28 % |
| 2018 | 41.01 % | -30.21 % | -30.07 % |
| 2017 | 37.27 % | -31.33 % | -30.94 % |
| 2016 | 45.15 % | -5.31 % | -25.37 % |
| 2015 | 47.77 % | 0.69 % | 1.13 % |
| 2014 | 50.01 % | 6.05 % | 23.45 % |
| 2013 | 48.58 % | 5.64 % | 5.83 % |
| 2012 | 48.29 % | -2.54 % | 4.25 % |
| 2011 | 49.13 % | 1.99 % | 7.87 % |
| 2010 | 50.14 % | 3.68 % | 9.44 % |
| 2009 | 49.76 % | 3.96 % | 8.35 % |
| 2008 | 40.55 % | -4.49 % | -15.19 % |
| 2007 | 43.72 % | -16.98 % | -40.1 % |
| 2006 | 52.4 % | -13.29 % | -16.02 % |
| 2005 | 49.1 % | 4.89 % | 4.51 % |
| 2004 | 45.38 % | -3.29 % | -1.22 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 45.38 % | -3.29 % | -1.22 % |
| 2005 | 49.1 % | 4.89 % | 4.51 % |
| 2006 | 52.4 % | -13.29 % | -16.02 % |
| 2007 | 43.72 % | -16.98 % | -40.1 % |
| 2008 | 40.55 % | -4.49 % | -15.19 % |
| 2009 | 49.76 % | 3.96 % | 8.35 % |
| 2010 | 50.14 % | 3.68 % | 9.44 % |
| 2011 | 49.13 % | 1.99 % | 7.87 % |
| 2012 | 48.29 % | -2.54 % | 4.25 % |
| 2013 | 48.58 % | 5.64 % | 5.83 % |
| 2014 | 50.01 % | 6.05 % | 23.45 % |
| 2015 | 47.77 % | 0.69 % | 1.13 % |
| 2016 | 45.15 % | -5.31 % | -25.37 % |
| 2017 | 37.27 % | -31.33 % | -30.94 % |
| 2018 | 41.01 % | -30.21 % | -30.07 % |
| 2019 | 41.29 % | -20.64 % | -20.28 % |
| 2020 | 42.81 % | -18.1 % | -17.41 % |
| 2021 | 42.36 % | -13.97 % | -9.7 % |
| 2022 | 44.53 % | -13.24 % | -13.25 % |
| 2023 | 42.04 % | -19.29 % | -18.45 % |
| 2024e | 42.04 % | -14.92 % | -17.31 % |
| 2025e | 42.04 % | -9.37 % | -8.52 % |
| 2026e | 42.04 % | -7.51 % | -8.46 % |
IRIDEX Aktienanalyse
What does IRIDEX do?
IRIDEX Corp is a global medical technology company that specializes in the development, manufacturing, marketing, and distribution of innovative laser-based medical devices and services. The company was originally founded in 1989 and is headquartered in Mountain View, California. IRIDEX's business model is divided into various divisions, each serving different markets. The divisions include ophthalmology, otolaryngology (ENT), gynecology and urology, as well as scientific research. The company offers a wide range of high-tech laser systems that can be used to treat various conditions, such as retinal diseases, glaucoma, nasal and throat disorders, gynecological and urological conditions, and other medical applications. One of the most well-known divisions of IRIDEX is ophthalmology, which offers a wide range of laser systems for the treatment of retinal diseases. These retinal diseases include diabetic retinopathy, retinal edema, age-related macular degeneration, and retinal detachment. The company also has a high-tech system called Cyclo G6TM, which is used for the treatment of glaucoma. This system can also be used in conjunction with other devices, such as ultrasound systems, for optimized clinical effectiveness. The ENT division offers laser systems for the treatment of nasal and throat disorders, such as snoring, polyps, stenosis, and tumors. The range of laser systems varies from simple systems to advanced systems that can be connected to a flexible endoscope for more precise treatment. IRIDEX's gynecology and urology division offers laser systems for various applications, such as urinary incontinence, bladder problems, tumor removal, prostate tissue removal, and medical treatments to improve sexual function. Laser systems can also be used in combination with other medical devices, such as ultrasound systems. The company places great emphasis on scientific research and development to create and introduce innovative technologies to the market. Therefore, IRIDEX collaborates closely with various research institutes, universities, and medical professionals to further develop its technological advances. The company is also committed to providing comprehensive training and support to its customers to ensure that they use the devices safely and effectively. Overall, IRIDEX Corp has established itself as an innovative and powerful multinational company in the field of medical technology. The company is constantly striving to expand its range of products and services and impress its customers with its high-quality solutions. IRIDEX is confident that it will continue to play a significant role in the medical technology industry in the future. IRIDEX ist eines der beliebtesten Unternehmen auf Eulerpool.com.Net Income Details
Understanding IRIDEX's Profit Margins
The profit margins of IRIDEX represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of IRIDEX's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Year-to-Year Comparison
Evaluating IRIDEX's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Impact on Investments
IRIDEX's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
Interpreting Profit Fluctuations
When IRIDEX’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Frequently Asked Questions about IRIDEX stock
How has the profit developed compared to last year?
The profit has increased by -8.5% compared to last year fallen
What impact do the earnings have on the shareholders?
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
How does IRIDEX publish its earnings?
IRIDEX publishes its earnings in the form of quarterly or annual reports.
Which financial indicators are included in the quarterly or annual reports?
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
Why is it important for investors to know the earnings of IRIDEX?
The profits of IRIDEX are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
How can one learn more about the earnings of IRIDEX?
You can learn more about the earnings of IRIDEX by reviewing the quarterly or annual reports or following the company presentations.
How much dividend does IRIDEX pay?
Over the past 12 months, IRIDEX paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IRIDEX is expected to pay a dividend of 0 USD.
What is the dividend yield of IRIDEX?
The current dividend yield of IRIDEX is .
When does IRIDEX pay dividends?
IRIDEX pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of IRIDEX?
IRIDEX paid dividends every year for the past 0 years.
What is the dividend of IRIDEX?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is IRIDEX located?
IRIDEX is assigned to the 'Health' sector.
Wann musste ich die Aktien von IRIDEX kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of IRIDEX from 10/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did IRIDEX pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of IRIDEX in the year 2023?
In the year 2023, IRIDEX distributed 0 USD as dividends.
In which currency does IRIDEX pay out the dividend?
The dividends of IRIDEX are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von IRIDEX
Our stock analysis for IRIDEX Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IRIDEX Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
